Fermenta Biotech (FERMENTA) Q2 FY27 Profit Halves as Margin Squeeze Bites
Sales grew 2% year-on-year, but net profit collapsed 48% as costs and overseas losses erased gains from a recovering human nutrition segment.
Fermenta Biotech's September quarter saw a slight revenue uptick, but profit fell by nearly half. The sharp margin contraction was driven by rising costs and losses in overseas subsidiaries, overshadowing growth in the core human nutrition business.
For a company built on nutritional ingredients, a quarter where sales grow but profit collapses is a story of costs outrunning pricing. Fermenta Biotech’s September quarter delivered exactly that tension, with revenue inching forward but net profit nearly halving year-on-year.
The numbers show a business under pressure. Consolidated revenue edged up 1.9% to ₹132.7 crore, while net profit fell 47.6% to ₹9.44 crore. The net profit margin compressed by 670 basis points to just 7.1%, a stark drop from 13.8% a year ago.
Revenue & profit
Revenue (₹ Cr)
Profit (₹ Cr)
Net Profit Margin (%)
| Metric | CurrentQ2 FY27 (Sep 2026) | PreviousQ1 FY27 (Jun 2026) |
|---|---|---|
| Revenue (₹ Cr) | 132.67 | 121.82 |
| Profit (₹ Cr) | 9.44 | 9.53 |
| Net Profit Margin (%) | 7.1 | 7.8 |
The Domestic Engine and the Overseas Drag
The story splits between a resilient standalone business and a troubled consolidated one. Standalone profit fell a milder 5.2%, as per StockWatch. The core domestic human nutrition segment grew, with its revenue share rising to nearly two-thirds of the total.
Yet, this strength was wiped out by losses elsewhere. The company’s three overseas units in the UK, Germany, and US swung to a combined net loss of ₹2.71 crore, notes StockWatch. The environment solutions subsidiary also remained a drag.
Why Margins Collapsed
Costs rose sharply across the board. Employee expenses jumped 17.9% year-on-year, while finance costs surged 44.7% to ₹3.73 crore. Other income, which includes items like insurance claims, fell 43.3%, removing a past cushion.
A sharp 52% drop in animal nutrition revenue, as reported in the company’s investor presentation, added to the pressure. Lower prices and volumes in this segment meant fixed costs were spread over a smaller base, squeezing margins further.
The Path Ahead
Management, via its presentation, is banking on new products. It expects capacity for its plant-based VITADEE Green® to come online from Q2 FY28. Another product, Calcifediol, is slated for regulatory readiness by FY27-end.
The balance sheet offers some relief. A Multibagg report notes net debt was below ₹3 crore as of September, with operating cash flow improving 44% in the first half. This provides a buffer as the company navigates the current profitability crunch.
Key Points
- Consolidated net profit fell 48% year-on-year despite a 2% rise in revenue, highlighting severe margin pressure.
- The profit decline was driven by a sharp contraction in the animal nutrition business, rising employee and finance costs, and losses in overseas subsidiaries.
- The standalone domestic business performed better, with human nutrition growth offsetting some of the consolidated weakness.
- The company maintains a strong net debt position and is investing in new product capacity for future growth.
Hexa Perspective
This quarter underscores a transition phase where legacy segment pressures are overwhelming core business gains. The near-term outlook hinges on whether human nutrition growth can accelerate enough to offset the animal nutrition slump and overseas losses.
The valuation, at a P/E of 12.7 against an industry average of 38.4, prices in significant skepticism. Investors are weighing the promise of new capacity against the clear evidence that current operations are struggling to convert sales into earnings.
Also read
Want this applied to your portfolio?
Talk to a HexaWealth advisor, or sync your mutual fund data for insights tailored to your holdings.
